Sanofi (NASDAQ:SNY) Shares Acquired by Forza Wealth Management LLC

Forza Wealth Management LLC increased its position in Sanofi (NASDAQ:SNY) by 147.3% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 9,235 shares of the company’s stock after purchasing an additional 5,500 shares during the period. Forza Wealth Management LLC’s holdings in Sanofi were worth $445,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Barrow Hanley Mewhinney & Strauss LLC lifted its holdings in shares of Sanofi by 113.8% in the 2nd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock worth $288,381,000 after purchasing an additional 3,164,092 shares during the last quarter. Franklin Resources Inc. boosted its stake in Sanofi by 13.1% during the 3rd quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company’s stock valued at $208,106,000 after purchasing an additional 395,744 shares in the last quarter. Envestnet Asset Management Inc. increased its position in shares of Sanofi by 8.2% during the 2nd quarter. Envestnet Asset Management Inc. now owns 3,252,326 shares of the company’s stock valued at $157,803,000 after purchasing an additional 246,224 shares during the period. Natixis Advisors LLC grew its holdings in Sanofi by 4.1% during the third quarter. Natixis Advisors LLC now owns 2,874,193 shares of the company’s stock worth $165,640,000 after acquiring an additional 114,133 shares during the period. Finally, Raymond James & Associates grew its stake in shares of Sanofi by 4.8% in the 3rd quarter. Raymond James & Associates now owns 2,819,348 shares of the company’s stock worth $162,479,000 after purchasing an additional 129,472 shares during the last quarter. 14.04% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on SNY. Citigroup upgraded Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Two investment analysts have rated the stock with a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Sanofi currently has a consensus rating of “Moderate Buy” and an average price target of $57.50.

Sanofi Stock Performance

SNY traded down $0.17 during midday trading on Monday, reaching $48.56. The company’s stock had a trading volume of 1,534,291 shares, compared to its average volume of 2,243,400. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The company has a fifty day simple moving average of $48.70 and a 200 day simple moving average of $52.11. The stock has a market cap of $123.24 billion, a P/E ratio of 24.78, a PEG ratio of 1.23 and a beta of 0.57. Sanofi has a twelve month low of $45.22 and a twelve month high of $58.97.

Sanofi (NASDAQ:SNY) last released its earnings results on Friday, October 25th. The company reported $1.57 EPS for the quarter, beating the consensus estimate of $0.22 by $1.35. The firm had revenue of $13.44 billion during the quarter, compared to analysts’ expectations of $16.59 billion. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The business’s quarterly revenue was up 12.3% compared to the same quarter last year. During the same period in the prior year, the company earned $2.55 EPS. Research analysts expect that Sanofi will post 4.06 earnings per share for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.